Literature DB >> 24663439

[Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012].

F Hoffmann1, G Glaeske.   

Abstract

OBJECTIVE: Previous analyses showed that benzodiazepine hypnotics as well as zolpidem and zopiclone (Z drugs) were increasingly being dispensed on so-called private prescriptions (Privatverordnungen) in Germany. Any doctor can provide private prescriptions for prescription drugs which are fully funded by the patient. This study aimed to analyze the amount of private prescriptions for hypnotics over the last 20 years.
METHODS: We compared utilization data from statutory health insurance claims with purchasing statistics from community pharmacies for the years 1993-2012.
RESULTS: From 1993 to 2012 purchased packages of hypnotics decreased (from 14.9 to 9.9 million). Benzodiazepines were dispensed less and Z drugs more often. In 2012 zopiclone (4.3 million packages of which 42.7 % were private prescriptions), zolpidem (3.6 million, 57.6 %) and lormetazepam (0.8 million, 57.8 %) were most often prescribed.
CONCLUSION: Trends in prescribing Z drugs are particularly noticeable whereby zolpidem was dispensed more often on private prescriptions than zopiclone. This seems to be further evidence for a higher dependence and abuse potential of zolpidem.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24663439     DOI: 10.1007/s00115-014-4016-8

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  15 in total

1.  [Structural differences between health insurance funds and their impact on health services research: results from the Bertelsmann Health-Care Monitor].

Authors:  F Hoffmann; A Icks
Journal:  Gesundheitswesen       Date:  2011-07-13

2.  [Use of zolpidem and zopiclone on private prescriptions between 1993 and 2007].

Authors:  F Hoffmann; W Scharffetter; G Glaeske
Journal:  Nervenarzt       Date:  2009-05       Impact factor: 1.214

3.  Sleep problems in general practice: a national survey of assessment and treatment routines of general practitioners in Norway.

Authors:  Børge Sivertsen; Inger H Nordhus; Bjørn Bjorvatn; Ståle Pallesen
Journal:  J Sleep Res       Date:  2009-08-31       Impact factor: 3.981

4.  Assessment of abuse potential of benzodiazepines from a prescription database using 'doctor shopping' as an indicator.

Authors:  Vincent Pradel; Catherine Delga; Frank Rouby; Joëlle Micallef; Maryse Lapeyre-Mestre
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

5.  Regional variations of private prescriptions for the non-benzodiazepine hypnotics zolpidem and zopiclone in Germany.

Authors:  Falk Hoffmann; Markus Hies; Gerd Glaeske
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-10       Impact factor: 2.890

6.  Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors.

Authors:  Anne M Hausken; Kari Furu; Svetlana Skurtveit; Anders Engeland; Jørgen G Bramness
Journal:  Eur J Clin Pharmacol       Date:  2008-09-23       Impact factor: 2.953

7.  [High usage of zolpidem and zopiclone. Cross-sectional study using claims data].

Authors:  F Hoffmann; M Pfannkuche; G Glaeske
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

8.  The use of benzodiazpines and related drugs amongst older people in Sweden: associated factors and concomitant use of other psychotropics.

Authors:  Kristina Johnell; Johan Fastbom
Journal:  Int J Geriatr Psychiatry       Date:  2009-07       Impact factor: 3.485

9.  [Long-term prescription of benzodiazepines and non-benzodiazepines].

Authors:  U Verthein; M S Martens; P Raschke; R Holzbach
Journal:  Gesundheitswesen       Date:  2012-08-03

10.  Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey.

Authors:  Olivia Boeuf; Maryse Lapeyre-Mestre
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more
  9 in total

1.  Pregabalin Use Among Users of Illicit Drugs: A Cross-Sectional Survey in Southern Germany.

Authors:  Brendan J Snellgrove; Tilman Steinert; Susanne Jaeger
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

2.  [Pain medication in nursing home residents with and without cancer. Most frequently with metamizole].

Authors:  J Schulze; M H Freitag; G Glaeske; G Schmiemann; F Hoffmann
Journal:  Schmerz       Date:  2015-07       Impact factor: 1.107

Review 3.  The problems of long-term treatment with benzodiazepines and related substances.

Authors:  Katrin Janhsen; Patrik Roser; Knut Hoffmann
Journal:  Dtsch Arztebl Int       Date:  2015-01-05       Impact factor: 5.594

4.  The Role of Private Prescriptions in Benzodiazepine and Z-Drug Use.

Authors:  Thomas Grimmsmann; Karel Kostev; Wolfgang Himmel
Journal:  Dtsch Arztebl Int       Date:  2022-05-27       Impact factor: 8.251

5.  Understanding and reducing the prescription of hypnotics and sedatives at the interface of hospital care and general practice: a protocol for a mixed-methods study.

Authors:  Stephanie Heinemann; Vivien Weiß; Kati Straube; Roland Nau; Thomas Grimmsmann; Wolfgang Himmel; Eva Hummers-Pradier
Journal:  BMJ Open       Date:  2016-08-05       Impact factor: 2.692

Review 6.  Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia.

Authors:  Catherine Roch; Giorgio Bergamini; Michel A Steiner; Martine Clozel
Journal:  Psychopharmacology (Berl)       Date:  2021-08-20       Impact factor: 4.530

7.  Eszopiclone for insomnia.

Authors:  Susanne Rösner; Christian Englbrecht; Renate Wehrle; Göran Hajak; Michael Soyka
Journal:  Cochrane Database Syst Rev       Date:  2018-10-10

8.  Prevalence and risk factors of drug-related problems identified in pharmacy-based medication reviews.

Authors:  Raphael Sell; Marion Schaefer
Journal:  Int J Clin Pharm       Date:  2020-02-05

Review 9.  Dependence liability of lormetazepam: are all benzodiazepines equal? The case of the new i.v. lormetazepam for anesthetic procedures.

Authors:  Reinhard Horowski
Journal:  J Neural Transm (Vienna)       Date:  2020-05-28       Impact factor: 3.575

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.